Heterogeneity of epithelial and stromal cells of head and neck squamous cell carcinomas in ex vivo chemoresponse
- 112 Downloads
Valid prediction of the effectiveness of chemotherapeutic agents in individual head and neck squamous cell carcinoma (HNSCC) is desirable and might be achieved using ex vivo assays.
Three biopsies from each of 15 HNSCC were taken, minced and digested by collagenase. The digested HNSCC was added to serial dilutions of either cisplatin (CIS) or docetaxel (DTX), which were prepared under flavin-protecting conditions in ECM-coated microtiterplates. After 72-h incubation, cultures were methanol-fixed and Giemsa-stained. The cutoff concentration (COC; concentration completely suppressing colony formation) for epithelial cells (EC) and stromal cells (SC) was evaluated.
12/15 HNSCC (80%) were evaluable. Despite significant correlation of COC of CIS in respect of colony formation of EC or SC, no significant differences in response of individual HNSCC specimens were found in the t test for paired samples (p > 0.16). The same applied to DTX. However, EC and SC showed heterogeneity in chemoresponses leading to COC variability of more than one titration step in 44.1% (CIS) and 20% of HNSCC (DTX). No significant correlation between the COC of both cell populations was found in HNSCC specimens.
The ex vivo chemoresponse of EC and SC of HNSCC must be analyzed separately.
KeywordsHeterogeneity HNSCC Ex vivo chemoresponse Epithelial cells Stromal cells
The authors wish to thank Anett Reiche and Grit Müller for their excellent technical assistance.
- 12.Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R, Pfreundner L, Schröder U, Eckel H, Hess M, Schröder M, Schneider P, Jens B, Zenner HP, Werner JA, Engenhardt-Cabillic R, Vanselow B, Plinkert P, Niewald M, Kuhnt T, Budach W, Flentje M (2009) Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol 266(8):1291–1300CrossRefPubMedGoogle Scholar
- 18.Dietz A, Tschöp K, Wichmann G, Granzow C (2008) Method and kit for the ex vivo evaluation of the response of a tumor to conditions to be tested. US-Provisional Ser. No. 61/044,082Google Scholar
- 19.Cabelguenne A, Blons H, Waziers De I, Carnot F, Houllier A-M, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P (2000) p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 18:1465–1473PubMedGoogle Scholar
- 20.Fouret P, Temam S, Charlotte F, Lacau-St-Guily J (2002) Tumor stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumor response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck. Br J Cancer 87:1390–1395CrossRefPubMedGoogle Scholar
- 21.Hoffmann TK, Sonkoly E, Hauser U, Lierop A, Whiteside TL, Klussmann JP, Hafner D, Schuler P, Friebe-Hoffmann U, Scheckenbach K, Erjala K, Gréman R, Schipper J, Bier H, Balz V (2008) Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol 44(12):1100–1109CrossRefPubMedGoogle Scholar
- 22.Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, Wu L, Sidransky D, Grandis JR (2004) Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck 26:870–877CrossRefPubMedGoogle Scholar
- 23.American Joint Committee on Cancer: Comparison Guide: Cancer Staging Manual Fifth versus Sixth Edition. http://www.cancerstaging.org/products/ajccguide.pdf. Accessed 31 March 2009
- 24.Dollner R, Kopun M, Dietz A, Wiessler M, Granzow C (2002) Chemoreactivity profiling of HNSCC: equipotentiality of platinum compounds and glufosfamide, a novel alkylating agent. Proc Am Assn Cancer Res 43:926–931Google Scholar
- 31.Granzow C, Kopun M, Heuser M, Herth F, Becker HD (2004) Chemoresistance of human lung tumor stromal cells. Am Assn Cancer Res 95th Annual Meeting Proc Suppl. abstract LB-82Google Scholar